Investigational CAR-T shows promise for advanced multiple myeloma

CHICAGO — A single dose of a novel chimeric antigen receptor T-cell therapy induced objective response among all treated patients with relapsed or refractory multiple myeloma, according to study results presented at ASCO Annual Meeting.
The investigational CAR-T exhibited a manageable safety profile, with limited cases of high-grade adverse events normally associated with adoptive cellular therapy, data from the phase 1 dose-escalation/dose-expansion study showed.
CART-ddBCMA (Arcellx) is an autologous, gene-edited CAR T-cell therapy that targets the B-cell maturation antigen (BCMA) on

CHICAGO — A single dose of a novel chimeric antigen receptor T-cell therapy induced objective response among all treated patients with relapsed or refractory multiple myeloma, according to study results presented at ASCO Annual Meeting.
The investigational CAR-T exhibited a manageable safety profile, with limited cases of high-grade adverse events normally associated with adoptive cellular therapy, data from the phase 1 dose-escalation/dose-expansion study showed.
CART-ddBCMA (Arcellx) is an autologous, gene-edited CAR T-cell therapy that targets the B-cell maturation antigen (BCMA) on